62060 Federal Register / Vol. 69, No. 204 / Friday, October 22, 2004 / Notices 

effort to decrease or eliminate the 

reservoir of latent infected cells with 

hope of perhaps eventually curing a 

patient of HIV infection. 

Treatment of Human Viral Infections 

(Proteosome Inhibitors) 

Drs. Steven Zeichner and Vyjayanthi 

Krishnan (NCI) 

U.S. Provisional Application No. 60/

587,810 filed 13 Jul 2004 (DHHS 

Reference No. E–280–2004/0–US–01) 

Licensing Contact: Sally Hu; 301/435–

5606; hus@mail.nih.gov.

This application describes the 

methods for treating or preventing an 

HIV infection by the administration of 

proteosome inhibitors and their 

derivatives. It has been known that HIV, 

once it infects a cell, integrates into the 

cellular genome and can (1) rapidly 

undergo lytic infection, or (2) lay 

dormant for a period of time (latent 

infection). The existence of latent 

infected cells poses a great challenge to 

HIV therapy because (1) there are no 

good existing means that can separate 

the latent infected cells from the 

uninfected cells; (2) even when 

antiretroviral drugs are able to 

completely suppress detectable HIV 

replication, these latent infected cells 

will remain and HIV can subsequently 

complete the viral replication cycle to 

produce more virus. Since proteosome 

inhibitors can activate lytic replication 

from latent infected cells, proteosome 

inhibitors may lead to therapies in 

which proteosome inhibitors are given 

together with highly active antiretroviral 

therapy in an effort to decrease or 

eliminate the reservoir of latent infected 

cells with hope of perhaps eventually 

curing a patient of HIV infection. 

Treatment of Human Viral Infections 

(Imatinib) 

Drs. Steven Zeichner and Vyjayanthi 

Krishnan (NCI) 

U.S. Provisional Application No. 60/

588,015 filed 13 Jul 2004 (DHHS 

Reference No. E–281–2004/0–US–01) 

Licensing Contact: Sally Hu; 301/435–

5606; hus@mail.nih.gov.

This application describes the 

methods for treating or preventing an 

HIV infection by the administration of 

abl-kinase inhibitor called imatinib and 

its derivatives. It has been known that 

HIV, once it infects a cell, integrates into 

the cellular genome and can (1) rapidly 

undergo lytic infection, or (2) lay 

dormant for a period of time (latent 

infection). The existence of latent 

infected cells poses a great challenge to 

HIV therapy because (1) there are no 

good existing means that can separate 

the latent infected cells from the 

uninfected cells; (2) even when 

antiretroviral drugs are able to 

completely suppress detectable HIV 

replication, these latent infected cells 

will remain and HIV can subsequently 

complete the viral replication cycle to 

produce more virus. Since imatinib and 

its derivatives can activate lytic 

replication from latent infected cells by 

activating NF–kB, imatinib and its 

derivatives may lead to therapies in 

which imatinib and/or its derivatives is 

given together with highly active 

antiretroviral therapy in an effort to 

decrease or eliminate the reservoir of 

latent infected cells with hope of 

perhaps eventually curing a patient of 

HIV infection. 

Treatment of Human Viral Infections 

(Farnesyl Transferase Inhibitors) 

Drs. Steven Zeichner and Vyjayanthi 

Krishnan (NCI) 

U.S. Provisional Application No. 60/

587,771 filed 13 Jul 2004 (DHHS 

Reference No. E–282–2004/0–US–01) 

Licensing Contact: Sally Hu; 301/435–

5606; hus@mail.nih.gov.

This application describes the 

methods for treating or preventing an 

HIV infection by the administration of 

farnesyl transferase inhibitors such as 

FTI277, L–744832, BMS214662, 

R115777 and SCH66336. It has been 

known that HIV, once it infects a cell, 

integrates into the cellular genome and 

can (1) rapidly undergo lytic infection, 

or (2) lay dormant for a period of time 

(latent infection). The existence of latent 

infected cells poses a great challenge to 

HIV therapy because (1) there are no 

good existing means that can separate 

the latent infected cells from the 

uninfected cells; (2) even when 

antiretroviral drugs are able to 

completely suppress detectable HIV 

replication, these latent infected cells 

will remain and HIV can subsequently 

complete the viral replication cycle to 

produce more virus. Since farnesyl 

transferase inhibitors can activate lytic 

replication from latent infected cells by 

modulating membrane-bound Ras–Rho 

levels, farnesyl transferase inhibitors 

may lead to therapies in which farnesyl 

transferase inhibitor is given together 

with highly active antiretroviral therapy 

in an effort to decrease or eliminate the 

reservoir of latent infected cells with 

hope of perhaps eventually curing a 

patient of HIV infection.

Dated: October 15, 2004. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health.

[FR Doc. 04–23650 Filed 10–21–04; 8:45 am] 

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel. Member 

Conflict Meeting. 

Date: November 17, 2004. 

Time: 6 p.m. to 8 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Ritz-Carlton Hotel at Pentagon City, 

1250 South Hayes Street, Arlington, VA 

22202. 

Contact Person: Mark Swieter, PhD, Health 

Scientist Administrator, Office of Extramural 

Affairs, National Institute on Drug Abuse, 

National Institutes of Health, DHHS, 6101 

Executive Boulevard, Suite 220, Bethesda, 

MD 20892–8401, (301) 435–1389.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse Research 

Programs, National Institutes of Health, HHS)

Dated: October 14, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–23654 Filed 10–21–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

Federal Register / Vol. 69, No. 204 / Friday, October 22, 2004 / Notices 62061

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Institute of 

General Medical Sciences Initial Review 

Group; Biomedical Research and Research 

Training Review Subcommittee A. 

Date: November 4–5, 2004. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn Chevy Chase, 5520 

Wisconsin Avenue, Chevy Chase, MD 20815. 

Contact Person: Carole H. Latker, PhD, 

Scientific Review Administrator, Office of 

Scientific Review, National Institute of 

General Medical Sciences, National Institutes 

of Health, Natcher Building, Room 3AN18, 

Bethesda, MD 20892, 301–594–2848, 

latkerc@nigms.nih.gov.

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.375, Minority Biomedical 

Research Support; 93.821, Cell Biology and 

Biophysics Research; 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.862, Genetics and 

Developmental Biology Research; 93.88, 

Minority Access to Research Careers; 93.96, 

Special Minority Initiatives, National 

Institutes of Health, HHS)

Dated: October 14, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–23655 Filed 10–21–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel, 

Services Conflicts 1. 

Date: November 12, 2004. 

Time: 1:30 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852, (Telephone 

Conference Call). 

Contact Person: Marina Broitman, PhD, 

Scientific Review Administrator, Division of 

Extramural Activities, National Institute of 

Mental Health, NIH, Neuroscience Center, 

6001 Executive Blvd., Room 6153, MSC 9608, 

Bethesda, MD 20892–9608, 301–402–8152, 

mbroitma@mail.nih.gov.

(Catalogue of Federal Assistance Program 

Nos. 93.242, Mental Health Research Grants; 

93.281, Scientist Development Award, 

Scientist Development Award for Clinicians, 

and Research Scientist Award; 93.282, 

Mental Health National Research Service 

Awards for Research Training, National 

Institutes of Health, HHS)

Dated: October 14, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–23656 Filed 10–21–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Dental & 

Craniofacial Research; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Institute of 

Dental and Craniofacial Research Special 

Emphasis Panel 05–24, Review of R13s. 

Date: November 12, 2004. 

Time: 10:30 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Natcher Building, 45 Center Drive, Bethesda, 

MD 20892, (Telephone Conference Call). 

Contact Person: Sooyoun (Sonia) Kim, MS, 

Associate SRA, Scientific Review Branch, 

Division of Extramural Research, National 

Inst. of Dental & Craniofacial Research, 

National Institute of Health, Bethesda, MD 

20892, (301) 594–4827.

Name of Committee: National Institute of 

Dental and Craniofacial Research Special 

Emphasis Panel 05–25, Review of R13s. 

Date: November 17, 2004. 

Time: 10 a.m. to 11:30 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Natcher Building, 45 Center Drive, Bethesda, 

MD 20892, (Telephone Conference Call). 

Contact Person: Sooyoun (Sonia) Kim, MS, 

Associate SRA, Scientific Review Branch, 

Division of Extramural Research, National 

Inst. of Dental & Craniofacial Research, 

National Institute of Health, Bethesda, MD 

20892, (301) 594–4827.

Name of Committee: National Institute of 

Dental and Craniofacial Research Special 

Emphasis Panel 05–23, Review of R13s. 

Date: December 7, 2004. 

Time: 3 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Natcher Building, 45 Center Drive, Bethesda, 

MD 20892, (Telephone Conference Call). 

Contact Person: Mary Kelly, Scientific 

Review Specialist, National Institute of 

Dental & Craniofacial Res., 45 Center Drive, 

Natcher Bldg., Rm. 4AN44, Bethesda, MD 

20892–6402, (301) 594–4809, 

mary_kelly@nih.gov.

Name of Committee: National Institute of 

Dental and Craniofacial Research Special 

Emphasis Panel 05–13, Review of RFA DE–

05–003, Oral Complications of HIV. 

Date: February 16–17, 2005. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott, 5151 Pooks Hill 

Road, Bethesda, MD 20814. 

Contact Person: Yujing Liu, MD, PhD, 

Scientific Review Administrator, National 

Institute of Dental & Craniofacial Res., 45 

Center Drive, Natcher Building, Rm. 4AN38E, 

Bethesda, MD 20892, (301) 594–3169, 

yujing_liu@nih.gov.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.121, Oral Diseases and 

Disorders Research, National Institutes of 

Health, HHS)

Dated: October 14, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–23657 Filed 10–21–04; 8:45 am] 

BILLING CODE 4140–01–M